
Anxiety disorders, encompassing generalised anxiety, panic disorder, social anxiety, and related conditions, are the most common mental health diagnoses globally, affecting over 300 million people. Pharmacological first-line treatment with SSRIs and SNRIs is well-established, while psychotherapy and digital mental health tools are expanding access. Novel agents targeting the GABAergic, glutamatergic, and orexin systems are under active investigation.
